BridgeBio looks to fully own its CV subsidiary Eidos

BridgeBio fell $2.94 (10%) to $26.88 Friday after proposing Thursday to fully acquire its cardiovascular-focused subsidiary Eidos, which climbed $3.11 (10%) to $35.17 on the news.

BridgeBio Pharma Inc. (NASDAQ:BBIO), which has a 66.6% stake in Eidos Therapeutics Inc. (NASDAQ:EIDX), offered to purchase the remaining outstanding shares at $38.31, a 20.9% premium over its close of $31.68 on Wednesday. The price values the acquisition at $472 million...